3 months Premium FREE
No credit card. No commitment.
Pfizer Inc
🇺🇸 PFE · NYSE/NASDAQ · US7170811035
Healthcare
Scores
Key Metrics
Powered by EODHDP/E (TTM)
37.0
P/E (Price-to-Earnings)Shows how much investors pay for each $1 of profit. We display the TTM P/E (Trailing Twelve Months) which uses actual earnings from the last 4 quarters. This is more reliable than Forward P/E which uses analyst estimates.
Net Debt/EBITDA (TTM)
4.1x
Latest quarter: 43.0x
Net Debt / EBITDAA leverage ratio showing how many years of EBITDA (earnings before interest, taxes, depreciation, and amortization) it would take to repay net debt. EBITDA approximates operating cash generation. Lower ratios (e.g., <3x) are generally safer; higher (e.g., >5x) may indicate more financial risk.
Latest quarter (2026-06-30): 43.0x
The quarterly value can spike when quarterly EBITDA is very low (e.g., one-time charges).
Quick guide: <2x manageable, >4x can be risky (sector-dependent).
ROE
5.0%
ROE (Return on Equity)A profitability measure: how much profit is generated from shareholders’ equity. Higher isn’t always better if it comes from high debt.
EV/EBITDA
15.7x
EV/EBITDAA valuation ratio that compares total business value (including debt) to EBITDA. Lower can mean cheaper, but context matters.
Dividend Summary
Powered by EODHDDividend Yield (Fwd)
6.82%
TTM: 6.09%
Dividend YieldThe Forward yield (Fwd) shows the next announced annual dividend / current price — what you'd earn going forward. The Trailing yield (TTM) in the tooltip shows dividends actually paid in the last 12 months. Forward is shown as primary because it reflects the company's current commitment to shareholders.
Forward Yield (estimated): 6.82%
Trailing Yield (TTM, last 12 months): 6.09%
Payout Ratio (Fwd)
56.4% TTM
Payout RatioDividends as a percentage of earnings. The Forward payout (Fwd) uses the announced dividend divided by actual past earnings (TTM) — it tells you if the company can afford what it promised. Very high payouts can be risky, especially if profits fall.
Announced dividend / actual earnings (TTM)
Dividend History
EODHD Dividends API| Status | Type | Decl. Date | Ex-Div Date | Pay Date | Currency | Amount |
|---|---|---|---|---|---|---|
| Forecast* | Quarterly | — | 24 Jul 2027 | — | USD | 0.43 |
| Forecast* | Quarterly | — | 08 May 2027 | — | USD | 0.43 |
| Forecast* | Quarterly | — | 23 Jan 2027 | — | USD | 0.43 |
| Forecast* | Quarterly | — | 07 Nov 2026 | — | USD | 0.43 |
| Declared | Quarterly | 24 Jun 2026 | 24 Jul 2026 | 01 Sep 2026 | USD | 0.43 |
| Paid | Quarterly | 22 Apr 2026 | 08 May 2026 | 12 Jun 2026 | USD | 0.43 |
| Paid | Quarterly | 12 Dec 2025 | 23 Jan 2026 | 06 Mar 2026 | USD | 0.43 |
| Paid | Quarterly | 09 Oct 2025 | 07 Nov 2025 | 01 Dec 2025 | USD | 0.43 |
* Extrapolated from past dividend history. Not an official announcement — treat as an estimate, not a confirmed date or amount.
Summary
Pfizer is a premier global pharmaceutical leader navigating a complex post-pandemic transition and upcoming structural patent cliffs. While elevated debt (4.08x Net Debt/EBITDA) and emerging legal liabilities require careful monitoring, headline metrics are temporarily depressed by a multi-billion dollar non-cash impairment, creating a compelling entry point with a 6%+ yield. Worth considering for new positions as a high-yield turnaround play.
Sector Context
Drug Manufacturers operate in a highly regulated, capital-intensive sector characterized by long development cycles and patent cliffs. While healthcare provides essential, recession-resistant cash flows ideal for DGI, pharmaceutical pipelines must constantly replenish revenue lost to generic competition and evolving pricing regulations.
Temporary Opportunity Identified
Headline earnings and the inflated 36.96x TTM P/E are severely distorted by a $4.3 billion one-time, non-cash intangible asset impairment in Q2 2026 and the final structural rebasing of pandemic-era COVID-19 product revenues.
📊 Strategy Analysis
- • Compelling valuation on a normalized basis with a Forward P/E of 9.57x, despite the distorted TTM P/E of 36.96x.
- • Attractive 6.09% TTM dividend yield (6.16% Forward), which is significantly above the company's 5-year historical average.
- • Cash flow dividend coverage remains intact with a Cash Flow Payout of 73.01% and an FCF coverage ratio of 1.12x, supported by $8.35B in Operating Cash Flow.
⚠ What to Watch
- • Severe structural patent cliffs impending between 2026 and 2030 (including Eliquis in 2028 and Ibrance in 2027) alongside IRA price cap impacts.
- • Elevated leverage with Net Debt/EBITDA expanding to 4.08x, constraining future capital flexibility and M&A capacity.
- • Mounting mass tort legal liabilities, notably the rapidly expanding Depo-Provera multidistrict litigation and the Oxbryta global recall/lawsuits.
📊 Historical Trends (10 Years)
Powered by EODHDThese charts show how key metrics have evolved over the past decade, helping you identify if the company is improving or deteriorating.
Debt Evolution (Net Debt / EBITDA)
Lower values are better. A declining trend indicates the company is reducing its debt (deleveraging).
Revenue & Earnings Growth
Consistent growth in revenueRevenue
The money a company brings in from selling its products or services. It’s the top line before costs. (blue) and earningsEarnings (Profit)
What’s left after expenses. Positive earnings mean the business made a profit; negative means a loss. (green) indicates a healthy business. Look for upward trends and recoveries after temporary dips.
Dividend Sustainability (FCF vs Dividends Paid)
Free cash flowFree Cash Flow
Cash left after the company pays for running the business and maintaining it. Often used to fund dividends, pay debt, or buy back shares. (FCFFCF (Free Cash Flow)
Short for Free Cash Flow: cash left after operating needs and maintenance spending., blue) should cover dividends paidDividends Paid
Cash the company paid out to shareholders. It’s not guaranteed and can change over time. (green). If dividends consistently exceed FCFFCF (Free Cash Flow)
Short for Free Cash Flow: cash left after operating needs and maintenance spending., the dividend may be at risk.
Analysis date: 2026-08-22
Disclaimer: This information is for educational purposes only. Not financial advice.